We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Rua Life Sciences Plc | LSE:RUA | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 1.77% | 11.50 | 11.00 | 12.00 | 12.25 | 11.25 | 11.50 | 704,699 | 09:48:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 2.19M | -1.44M | -0.0232 | -4.96 | 7.01M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/6/2024 10:49 | Almost 10% awarded at rock bottom price and you think any investor should be excited | cocker | |
19/6/2024 10:03 | ”All outstanding Options shall be exercisable on the expiry of the period of 3 years from the Date of Grant, with the usual acceleration of vesting in the event of a takeover prior to the final vesting date. Additionally, if a return of capital is proposed at an amount per share that is greater than the exercise price per share of these options, they will vest immediately prior to such return of capital to allow option holders to participate.” Getting their options in place ahead of such possibilities? | bones | |
19/6/2024 09:15 | Nice to see the nest getting kicked, GLA | lawson27 | |
10/6/2024 13:03 | For all we know, they are huddled together with cold wet towels on their heads thrashing out the final terms of a megadeal and the last thing that needs is an update until finalised. Or, they might be doing not a lot apart from answering the auditor’s questions and putting final touches to the accounts. Or, they are playing golf at one of the fine courses littering the Ayrshire coast. Take your pick or pick your club. | bones | |
10/6/2024 12:24 | Maybe you are right and RUA will assume investors will conclude that final results will come in July. I, however, would expect them to state this as they, and to my knowledge every other AIM listed company (and possible to comply with AIM rules), have done previously. | hedgehog11 | |
07/6/2024 12:59 | Well, not today. I'm wearing three or four pairs of rose tinted glasses so my conspiracy theory is they are waiting for expected good news to land before announcing the year end results. Basically, I think it's triplets. | hedgehog11 | |
07/6/2024 09:15 | pregnant with news one would hope | thiopia | |
06/6/2024 14:57 | Set your alarms for 7:30 tomorrow, the date marks the latest in recent years RUA have notified of year end results, so maybe there will be one tomorrow - is it too much to hope that they are/have been expecting some positive news and are waiting to include it in the RNS! I'll be looking for progress in contract manufacturing and protecting that cash balance, the former would push the share price to a new level. | hedgehog11 | |
31/5/2024 09:11 | All blue this morning, would be nice to see a significant bounce off this years trading range, GLA | lawson27 | |
28/5/2024 10:33 | The “ Hammermen of Glasgow “ sound sinister! | bones | |
28/5/2024 08:08 | "transitioning to commercialisation" :o) | davisc5 | |
28/5/2024 07:49 | The Scottish Engineering Awards 2024 took place last week: ”Our 2024 Young Engineer of the Year Award (YEYA24) in partnership with The Incorporation of Hammermen of Glasgow was presented to Ross McPhillie of RUA Life Sciences for his role in developing a prosthetic heart valve prototype that is transitioning to commercialisation. Bruce Wood, Deacon of The Incorporation of Hammermen of Glasgow, added: “Once again the standard of young engineers entering the competition has been inspiring, with outstanding presentations revealing the depth of engineering talent that Scotland can be proud of. Choosing a winner amongst such high standards is always difficult, but in Ross McPhillie of RUA Life Sciences, we have a worthy winner. “Ross aimed to innovate heart valve technology by developing a prototype which successfully lasted 200 million cycles in durability tests and is now transitioning to commercialisation. Alongside Ross, all our finalists, should be proud of their outstanding achievements and they are a true inspiration to Scottish engineers, young and not so young.” | bones | |
28/5/2024 07:24 | 14p seems to be the blocker, let's see. | davisc5 | |
24/5/2024 10:27 | Come on let's have some news now. The chart is set up perfectly for it.Could see an almighty spike. Fingers crossed. | parob | |
22/5/2024 11:08 | Joined you for a few @13 on the breakout here, GLA | lawson27 | |
22/5/2024 09:19 | After yesterday's PM sell off there does seem to be some determined buying so far today. And more round number buying which is good (imo)- not the usual PI trading in odd amounts to match the cash available. | langland | |
22/5/2024 08:57 | Just need the right news now and this will spike massively imo. | parob | |
21/5/2024 14:03 | Caroline did mention years ago that a major was coming to town, perhaps their transport was a mobility scooter & as a result have only just arrived. | cocker | |
21/5/2024 13:11 | Agreed langland. RUAs valuation is chump change. Why give RUA the margin when Edwards can buy the margin lock stock and barrel. OD | obiterdicta | |
21/5/2024 12:31 | Perhaps not replacing Caroline Stretton aligns with that argument too? | gleach23 | |
21/5/2024 12:22 | The way I see it is that this 'material transfer agreement' is merely a means by which the major heart player (Edwards) is able to do its due diligence on RUA. Rua talks about getting other agreements in place but really I think we are talking about a complete buy out of RUA. Why would a heart valve company (valued in the billions) mess about with trying to do a licensing deal when it can buy the whole company for peanuts effectively. | langland | |
21/5/2024 11:24 | RUA and PHE having a strong breakout now.....in for a strong rally this afternoon.....nice to see | citys2874 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions